Entering text into the input field will update the search result below

Repligen selects Purolite Life Sciences as commercial partner for new high performance ligand

Jun. 28, 2018 7:35 AM ETRepligen Corporation (RGEN) StockBy: Niloofer Shaikh, SA News Editor
  • Repligen (NASDAQ:RGEN) entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact A.
  • Tony J. Hunt, Repligen CEO, said, “We are delighted by this agreement with Purolite Life Sciences, which is a natural extension of our existing Protein A supply agreement with them. We look forward to seeing how this next-generation ligand performs in the marketplace with Purolite Life Sciences’s Praesto jetted agarose bead technology.”
  • Press Release

Recommended For You

More Trending News

About RGEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RGEN--
Repligen Corporation